VEPESID CAPSULE
Negara: Kanada
Bahasa: Inggris
Sumber: Health Canada
Karakteristik produk
(SPC)
18-12-2019
Beberapa dokumen untuk produk ini saat ini tidak tersedia, Anda dapat mengirim permintaan ke layanan pelanggan kami dan kami akan memberi tahu Anda segera setelah kami bisa mendapatkannya.
Kirim permintaan.
Kirim permintaan.
Bahan aktif:
ETOPOSIDE
Tersedia dari:
CHEPLAPHARM ARZNEIMITTEL GMBH
Kode ATC:
L01CB01
INN (Nama Internasional):
ETOPOSIDE
Dosis:
50MG
Bentuk farmasi:
CAPSULE
Komposisi:
ETOPOSIDE 50MG
Rute administrasi :
ORAL
Unit dalam paket:
20
Jenis Resep:
Prescription
Area terapi:
ANTINEOPLASTIC AGENTS
Ringkasan produk:
Active ingredient group (AIG) number: 0114567001; AHFS:
Status otorisasi:
APPROVED
Tanggal Otorisasi:
2008-08-12
Karakteristik produk
PRODUCT MONOGRAPH
PR VEPESID*
(Etoposide Capsules)
Capsule, 50 mg
ANTINEOPLASTIC AGENT
Date of Revision:
December 18, 2019
CHEPLAPHARM Arzneimittel GmbH
Ziegelhof 24, 17489 Greifswald, Germany
* Registered TM of CHEPLAPHARM Arzneimittel GmbH
Distributed by Xediton Pharmaceuticals Inc,
2000 Argentia Rd, Mississauga, Ontario L5N 1W1
Submission Control Number: 233295
TABLE OF CONTENT
THERAPEUTIC CASSIFICATION
..............................................................................................
3
ACTIONS AND CLINICAL PHARMACOLOGY
..........................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
4
CONTRAINDICATIONS
.............................................................................................................
4
WARNINGS
...............................................................................................................................
4
PRECAUTIONS
.........................................................................................................................
6
DRUG INTERACTIONS
.............................................................................................................
7
ADVERSE REACTIONS
............................................................................................................
8
SYMPTOMS AND TREATMENT OF OVERDOSAGE
..............................................................10
DOSAGE AND ADMINISTRATION
...........................................................................................11
PHARMACEUTICAL INFORMATION
.......................................................................................12
SPECIAL INSTRUCTIONS
.......................................................................................................13
AVAILABILITY OF DOSAGE FORMS
.......................................................................................13
HUMAN PHARMACOLOGY
........................................
Baca dokumen lengkapnya
